Guided by previous evidence on the therapeutic impact of a drug combination approach in ALK+ tumors [9,12,23,36,37,38], we investigated the potentialities of upfront combined treatments by testing four distinct drug combinations on different ALK+ ALCL cell lines. This evidence concerns the gene ALK and anaplastic large cell lymphoma.